HANALL BIOPHARMA Co., Ltd.

In this morning’s first-quarter earnings release, Immunovant confirmed that the road has run out for batoclimab. \n Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped, a month after the asset flunked a pair of phase 3 eye disease trials.The company first set out plans back in 2022 to assess the therapy, called batoclimab, in two late-stage studies of patients with thyroid eye disease (TED). But Immunovant’s majority shareholder, Roivant, disclosed in early April that both trials had missed their primary endpoint of demonstrating a 2 mm or greater reduction in proptosis, a term for eye bulging.TED is an immunoglobulin G (IgG)-mediated autoimmune condition. Last month, Roivant suggested that greater improvements in proptosis were seen after the high-dose period in the studies than after the low-dose period, meaning the data support “the benefit of deeper IgG suppression.”The company didn’t appear willing to write off batoclimab completely, only saying in its April statement that it intended to “review future plans for the development of batoclimab” with its Korea-based partner, HanAll, and that it would provide an update “at a future date.”  But in this morning’s first-quarter earnings release, Immunovant confirmed that the road has run out for batoclimab. The biotech also noted that discontinuing the program had resulted in paying out $39 million in related contractual costs. These helped drive up R&D expenses for the fiscal year ending March 31 to $456.7 million compared with $360.9 million for the previous-year period.Immunovant tried not to paint batoclimab as a totally wasted effort. Instead, the company said that learnings from the program, including its “clinical data, operational trial experience and relationships with investigators,” could be “leveraged to inform the development” of its second-generation FcRn blocker, IMVT-1402.Topline data from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus are expected in the second half of this year, while a readout for a phase 2b study in Graves’ disease is penciled in for next year and a study in difficult-to-treat rheumatoid arthritis (RA) is also ongoing.The company offered a slice of preliminary data from the RA study this morning, which showed that 72.7% of the study’s 170 heavily pre-treated patients had seen at least a 20% improvement in symptoms at Week 16, with 54.5% seeing a 50% or greater improvement. Investors appeared enthused by the findings, sending Immunovant’s stock up 20% to $31.71 in pre-market trading Wednesday from a Tuesday closing price of $26.29.With $902.1 million in the bank, Immunovant said it has enough cash to continue to explore each of these indications up to a hoped-for commercial launch of IMVT-1402 in Graves’ disease.Still, scrapping batoclimab is another blow to attempts to get an FcRn inhibitor approved for TED after argenx discontinued studies of Vyvgart for the eye condition after they appeared set to miss their goals. The writing had been on the wall for batoclimab for a while, with Immunovant having written off any chances of pursuing the drug to treat myasthenia gravis despite the drug notching a phase 3 win for the IgG-driven disorder.

This morning’s double trial failure is another blow to attempts to get a FcRn inhibitor approved for thyroid eye disease.\n Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug.The company set out plans back in 2022 to assess the therapy, called batoclimab, in two late-stage studies of patients with thyroid eye disease (TED). This morning, Immunovant’s majority shareholder, Roivant, revealed that both trials had missed their primary endpoint of demonstrating a 2 mm or greater reduction in proptosis—a term for eye bulging—after 12 weekly doses of high-dose batoclimab followed by 12 weeks of a low dose.Patients in the studies were randomized to receive either the treatment or placebo. No new safety signals were identified, Roivant noted.The company pointed out that greater improvements in proptosis were seen after the high-dose period than after the low-dose period. This “support[s] the benefit of deeper IgG suppression,” Roivant concluded. TED is an immunoglobulin G (IgG)-mediated autoimmune condition. When specifically looking at hyperthyroid patients, Roivant said that batoclimab demonstrated thyroid hormone normalization rates similar to those seen in a phase 2 study of the therapy in Graves’ disease, a condition that leads to TED. Batoclimab did score a phase 3 win in March 2025 in myasthenia gravis, another IgG-driven disorder. But by that point, Immunovant had decided not to commercialize batoclimab in this condition. While it already sounded like Immunovant had lost enthusiasm for the asset, the company said at the time that it was holding off making a decision on whether to pursue batoclimab in TED until it saw today’s phase 3 results.The following month, batoclimab’s future sounded even bleaker. As Roivant took tighter control of the spinout by installing its own CEO, the company explained that development activities for the asset could “begin to conclude.”According to this morning’s release, Immunovant now “intends to review future plans for the development of batoclimab” with its Korea-based partner HanAll and provide an update “at a future date.”  TED can cause muscles that control the eye and fat behind the organ to grow abnormally, and it can also lead to orbital inflammation. This can in turn cause proptosis, double vision or, in severe cases, vision loss.This morning’s double trial failure is another blow to attempts to get an FcRn inhibitor approved for TED after argenx discontinued studies of Vyvgart for the eye condition after they appeared set to miss their goal.Under a closer alignment with Roivant, Immunovant has been focusing its resources on a second-generation FcRn blocker dubbed IMVT-1402. Topline data from phase 2b studies of IMVT-1402 in Graves’ disease are expected next year, Roivant confirmed in this morning’s release.  

Immunovant’s batoclimab failed in two late-stage trials in thyroid eye disease (TED). It already said it probably wasn’t going to advance the drug further in a similar condition called Graves’ disease. The company said Thursday it would discuss batoclimab’s future with its partner, the South Korean drugmaker HanAll Biopharma. The Phase 3 trials, called GO-1 and GO-2, were designed to show that batoclimab could improve a TED symptom called proptosis, where the patient’s eyes bulge from their sockets. Patients were given a 680 mg injection of the drug every week for three months, followed by half that dose for the same period. At the six-month mark, the proptosis improvement endpoint was not met. Immunovant did say that batoclimab recipients had more of an improvement on the proptosis measure after the study’s high-dose period than they did after the subsequent low-dose period, suggesting a dose response. The company’s shares $IMVT were down by as much as 11% in premarket trading Thursday. Immunovant said in September that it was focusing its Graves’ disease efforts on a next-generation candidate with the same mechanism as batoclimab, known as IMVT-1402. A year ago, it also said it was dropping batoclimab in the autoimmune disorder myasthenia gravis, again in favor of IMVT-1402. Both candidates aim to block the neonatal Fc receptor, which should reduce circulating levels of pathogenic IgG autoantibodies and combat IgG-mediated diseases like TED and Graves. IMVT-1402 is in Phase 2 trials in Graves’ disease, which Immunovant said are potentially registrational. Investors will get the chance to see whether this product works better than its predecessor when the first data from those trials emerge next year. Meanwhile, another company under Roivant’s “vant” umbrella, Priovant, said Thursday it had started a Phase 2b/3 trial of a drug called brepocitinib, which could support the drug’s approval in the scalp condition lichen planopilaris (LPP). In LPP, hair follicles are destroyed and replaced with scar tissue, causing itching or burning sensations and permanent hair loss. The disorder can also increase the risk of other autoimmune diseases and skin cancers. It mostly affects people aged 40 to 60 and is more common in women than men, and Priovant said roughly 100,000 US adults have LPP. There are no approved treatments. Brepocitinib is a dual JAK1/TYK2 inhibitor. It is due an approval decision in the third quarter of this year for the inflammatory condition dermatomyositis. Priovant said it could launch in in September. The drug is also being researched in non-infectious uveitis and cutaneous sarcoidosis. Editor’s note: This article was updated to include Immunovant’s share price change.